Assessment of Hepatic Fibrosis Regression by Transient Elastography in Patients with Chronic Hepatitis B Treated with Oral Antiviral Agents by 源��옄寃� & �씠愿��떇
© 2014 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Assessment of Hepatic Fibrosis Regression by Transient 
Elastography in Patients with Chronic Hepatitis B Treated  
with Oral Antiviral Agents 
Transient elastography (TE) has been used as a non-invasive method for liver stiffness 
measurement (LSM) in patients with chronic liver disease. This study was performed to 
assess the change of LSM by TE and to assess its clinical usefulness during long-term oral 
antiviral therapy in patients with chronic hepatitis B (CHB). We retrospectively reviewed 83 
CHB patients. The mean interval between two LSM was 411.5 ± 149.5 days. Initial and 
follow-up LSM was 16.15 ± 12.41 kPa and 11.26 ± 7.36 kPa, respectively (P < 0.001). The 
degree of regression of liver stiffness was -2.03 ± 0.36% per month. The fibrosis stage 
classified by LSM value improved in 37 (44.6%) patients during oral antiviral therapy. Of 
the 30 (36.1%) patients with LSM ≥ 14.1 kPa (cirrhosis) at 1st LSM, 12 (40%) proved to no 
longer have cirrhosis (≥ 1 decrease in fibrosis stage) at 2nd LSM. LSM significantly 
decreased in both baseline high (> upper limit of normal [ULN] × 2) and low (≤ ULN × 2) 
alanine aminotransferase groups during antiviral therapy (P < 0.001; P = 0.001, 
respectively). Long-term oral antiviral therapy resulted in the improvement of liver stiffness 
in a substantial portion of patients with CHB. TE may be used a useful clinical tool to assess 
disease progression in CHB patients.
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INTRODUCTION
Chronic hepatitis B (CHB) often leads to serious health condi­
tions including decompensated liver cirrhosis and hepatocel­
lular carcinoma (HCC) (1). Host immune response to HBV in­
fected hepatocytes results in hepatocyte apoptosis and necrosis 
that activates nonparenchymal cells including hepatic stellate 
cells to produce extracellular matrix such as type I collagen re­
sulting in hepatic fibrosis (2, 3). Hepatic fibrogenesis is a dyna­
mic process with a net result of fibrotic scar formation. Resolu­
tion of scars determines the progression from hepatic fibrosis 
to liver cirrhosis (4). The suppression of viral replication by long­
term antiviral therapy may improve hepatic inflammation and 
fibrosis and halt the progression of disease to decompensated 
liver cirrhosis and HCC (5, 6). Lamivudine treatment decreased 
complications from portal hypertension and the development 
of liver cancer in patients with compensated liver cirrhosis, al­
though the benefit was less in patients who develop lamivudine 
resistance (7). Entecavir treatment for 48 weeks in patients with 
advanced hepatic fibrosis or cirrhosis showed the improvement 
of liver histology in 57% with HBeAg+ve, 59% with HBeAg­ve, 
and 43% of patients with lamivudine­resistant CHB (8). 
 Accurate information about the hepatic fibrosis stage is very 
important in clinical practice because the extent of hepatic fi­
brosis predicts the development of hepatic decompensation 
and HCC in patients with CHB (9, 10). Liver biopsy has been a 
gold standard to assess the extent of hepatic fibrosis (11). How­
ever it is hard to perform liver biopsy repeatedly in patients with 
CHB because of its invasive nature. Instead, the assessment of 
liver stiffness using fibroscan has been reported as a relevant 
non­invasive tool for the assessment of hepatic fibrosis in vari­
ous kinds of chronic liver disease including hepatitis B, hepati­
tis C, and alcoholic liver disease (12). In this study we aimed to 
evaluate the regression of hepatic fibrosis through repeated liv­
er stiffness measurement (LSM) using fibroscan during long­
term oral antiviral therapy in patients with CHB. 
MATERIALS AND METHODS
Patients 
From October 2007 to February 2011, a total of 3,156 LSM was 
performed in Gangnam Severance Hospital, Seoul, Korea. Eighty 
eight CHB patients on oral nucleos(t)ide therapy who received 
LSM twice were retrospectively enrolled. Five patients who had 
the interval between the first and the second LSM was shorter 
than 6 months, were excluded. No patients were positive to an­
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ti­hepatitis C virus (HCV) antibody (Ab) or anti­human immu­
nodeficiency virus Ab. Finally, 83 patients were included in this 
study. We retrospectively reviewed the medical records and an­
alysed the change of liver stiffness measured by transient elas­
tography (Fibroscan®, Echosens, France). The patients were fol­
lowed up every 3 months with serologic tests. When virologic 
breakthrough due to the development of antiviral drug resistance 
was confirmed, nucleos(t)ide analogue was added or changed 
according to resistant mutation.
Laboratory tests
HBsAg and HBeAg/Ab were determined by enzyme immuno­
assay (Dade Behring, Marburg, Germany). Serum HBV DNA 
was measured by a real­time polymerase chain reaction assay 
using a COBAS TaqMan 48 analyzer (Roche Diagnostics, Mann­
heim, Germany) with a detection limit of 12 IU/mL. The anti­
body against HCV was detected by a third­generation enzyme­
linked immunosorbent assay (Korea Greencross, Yong­in, Ko­
rea). 
Liver stiffness measurement (LSM)
Well trained and experienced physicians obtained all LSM ac­
cording to the instructions provided by the manufacturer. All 
patients received LSM using FibroScan® two times during oral 
nucleos(t)ide antiviral therapy. The first LSM was performed 
before the starting antiviral therapy (n = 33, 39.8%) or during 
follow up visit on antiviral therapy (n = 50, 60.2%). The timing 
of the 2nd LSM was decided by physician’s or patient’s discre­
tion to monitor liver stiffness. The mean interval between the 
first and the second LSM was 411.5 ± 149.5 (range: 180­1,062) 
days. LSM was performed on the right lobe of the liver through 
the intercostal spaces on patients lying in the dorsal decubitus 
position with the right arm in maximal abduction (13). The re­
sults are expressed as kilopascals (kPa). The extent of liver fibro­
sis was classified according to the METAVIR scoring system (F0­
F4). Transient elastography cut­off levels used for staging liver 
fibrosis ≥ F2, ≥ F3, and F4 were 8.8, 10.2, and 14.1 kPa, respec­
tively (14).
 The interquartile range (IQR) was defined as an index of in­
trinsic variability of LSM corresponding to the interval of LSM 
results containing 50% of the valid measurements between the 
25th and 75th percentiles. The median LSM was selected as 
representative of the LSM value in a given patient. In this study, 
only LSM examinations with at least ten validated measurements, 
an IQR to median value ratio (IQR/M) was less than 0.3, and a 
success rate of at least 60% were considered reliable and were 
included for the analysis. 
Statistics
Data were analyzed using the statistical software SPSS (version 
13.0, SPSS Inc., Chicago, IL, USA). Quantitative variables are ex­
pressed as mean ± standard deviation. The degree of difference 
of LSM between two time points (% per month) was calculated 
as follows; 
 (2nd stiffness­1st stiffness) × 100/1st stiffness 
                                (2nd date­1st date)/30.5
 Data were analyzed using paired t­test, Wilcoxon signed rank 
test, Mann­Whitney U test, oneway ANOVA, and chi­square test. 
Data were considered to be statistically significant with P < 0.05. 
Ethics statement
This study conformed to the ethical guidelines of the 1975 Dec­
laration of Helsinki and was approved by the institutional re­
view board at Gangnam Severance Hospital, Seoul, Korea (3­
2013­0269). Informed consents were waived by the board.
RESULTS
Baseline characteristics of the patients
The baseline characteristics of the 83 patients are presented in 
Table 1. There were 61 men and 22 women, with a mean age of 
51.5 ± 9.1 yr. The mean interval between two LSMs was 411.5 
± 149.5 (180­1,062) days. The number of patients received anti­
viral therapy as follows; entecavir 0.5 mg in 28 (33.7%), lamivu­
dine in 22 (26.5%), clevudine in 14 (16.9%), adefovir in 4 (4.8%), 
lamivudine plus adefovir in 11 (13.3%), and entecavir 1.0 mg in 
4 (4.8%) patients. Eighty patients (96.4%) showed serum HBV 
DNA below 2,000 IU/mL at 2nd LSM.
Comparison of clinical parameters between two LSMs 
during antiviral therapy
Clinical parameters and liver stiffness values are demonstrated 
in Table 2. During the antiviral therapy, aspartate aminotrans­
ferase (AST), alanine aminotransferase (ALT), total bilirubin, 
and HBV DNA levels were decreased. Accordingly, serum albu­
Table 1. Baseline characteristics of patients
Characteristics No. (%) of patients
Sex (M:F) 61:22
Age (yr, mean ± SD, range) 51.5 ± 9.1 (30-69)
HBeAg positivity (%) 44/83 (53)
LSM intervals (days) (mean ± SD, range) 411.5 ± 149.5 (180-1,062) 
Ultrasonography finding
   Normal echogenicity
   Fatty change only
   Diffuse liver disease
   Liver cirrhosis
   Hepatocellular carcinoma
2 (2.4)
7 (8.5)
27 (32.5)
45 (54.2)
2 (2.4)
Antiviral therapy 
   Entecavir 0.5 mg   
   Lamivudine
   Clevudine
   Adefovir 
   Lamivudine+Adefovir
   Entecavir 1.0 mg 
28 (33.7)
22 (26.5)
14 (16.9)
4 (4.8)
11 (13.3)
4 (4.8)
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min levels and platelet count increased during the antiviral ther­
apy. Liver stiffness values significantly decreased from 16.15 ±  
12.41 kPa to 11.26 ± 7.36 kPa during the antiviral therapy (P <  
0.001). Sixty­two (74.7%) patients had a lower liver stiffness val­
ue at 2nd LSM compared to 1st LSM. The degree of regression 
of liver stiffness value was ­2.03 ± 0.36 (­10.25~8.83)% per month. 
There was no difference of the degree of regression of liver stiff­
ness between the patients in whom initial LSM was obtained 
before starting antiviral therapy (n = 33) and the patients in whom 
initial LSM was obtained during antiviral therapy (n = 50) (­2.54 
± 3.13 vs ­1.69 ± 3.35% per month, P = 0.251). The difference of 
liver stiffness value between 1st and 2nd LSMs by the type of 
antiviral agents is summarized in Fig. 1. The differences of two 
LSM values were all negative regardless of antiviral agents. How­
ever, there was no significant difference according to the kind of 
antiviral agents (P = 0.625) or lamivudine resistance (P = 0.078). 
 Of the 30 (36.1%) patients with LSM ≥ 14.1 kPa (cirrhosis) at 
1st LSM, 25 (83.3%) had a lower LSM value and 12 (40%) proved 
to no longer have cirrhosis ( ≥ 1 decrease in fibrosis stage) at 
2nd LSM. 
Comparison of groups according to the change of LSM 
value during antiviral therapy
We compared the clinical parameters according to the presence 
of the improvement of LSM value during antiviral therapy (Ta­
ble 3). Sixty two (74.7%) patients had a decrease in liver stiffness 
value (group 1), whereas 21 (25.3%) showed an increase in liver 
stiffness value (group 2) during antiviral therapy. There was no 
difference in sex, age, LSM intervals, baseline laboratory pro­
files including AST, ALT, total bilirubin, HBeAg positivity, HBV 
DNA levels between two groups. Only 1st LSM value was higher 
in group 1 (P = 0.012), and 2nd LSM value was lower in group 1 
compared to group 2 (P = 0.005). 
Comparison of groups according to the change of fibrosis 
stage during antiviral therapy
The patients’ initial fibrosis stages were 16 (19.3%) in F0­1, 15 
(18.1%) in F2, 22 (26.5%) in F3 and 30 (36.1%) in F4, respective­
ly. After antiviral therapy, the patients’ fibrosis stages were 42 
(50.6%) in F0­1, 6 (7.2%) in F2, 12 (14.5%) in F3 and 23 (27.7%) 
in F4, respectively (Fig. 2). The fibrosis stage was improved in 37 
(44.6%) between two LSMs. Thirty eight (45.8%) patients show­
ed no change of fibrosis stage, only 8 (9.6%) showed the aggra­
vation of fibrosis stage. Among these 8 patients, their initial ul­
trasonographic findings were diffuse liver disease in 2 patients, 
and liver cirrhosis in 6 patients. The antiviral treatment for these 
8 patients was as follows; lamivudine for 2 patients, clevudine for 
2 patients, entecavir for 2 patients, adefovir for one patient, and 
lamivudine and adefovir combination for one patient. Clinical 
parameters according to the improvement of fibrosis stage were 
compared (Table 4). There was no difference in age, LSM inter­
vals, initial laboratory profiles including AST, ALT, total biliru­
bin, HBeAg positivity, and HBV DNA levels. However, patients 
Table 2. Comparison of parameters between two LSMs during antiviral therapy
Parameters 1st LSM 2nd LSM P value
Liver stiffness (kPa) 16.15 ± 12.41 11.26 ± 7.36 < 0.001
Albumin (g/dL) 4.27 ± 0.49 4.52 ± 0.33 < 0.001
Total bilirubin (mg/dL) 1.35 ± 1.53 0.99 ± 0.38 0.040
AST (IU/L) 81.46 ± 185.4 29.04 ± 10.98 0.012
ALT (IU/L) 100.94 ± 267.31 28.61 ± 14.35 0.016
Platelet (103/µL) 158.66 ± 57.76 172.34 ± 60.11 < 0.001
HBV DNA (IU/mL)* 3,994 12 < 0.001
Duration of antiviral treatment*  
   (months)
5.3    17.3 < 0.001
*Median. AST, aspartate aminotransferase; ALT, alanine aminotransferase; LSM, liver 
stiffness measurement.
Fig. 1. The difference of liver stiffness values between the first and the second mea-
surement using transient elastography (Fibroscan®) by the type of antiviral agents. 
The differences of two LSM values were all negative values regardless of antiviral 
agents. However, there was no significant difference according to the kind of antiviral 
agents (P = 0.625) or lamivudine resistance (P = 0.078).
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Table 3. Comparison of groups by LSM change during antiviral therapy 
Parameters
LSM decreased 
(n = 62)
LSM increased 
(n = 21)
P value
Male gender (%) 72.6 76.2 1.000
Age (yr) 51.29 ± 8.75 52.14 ± 10.32 0.714
Measurement intervals (day) 401.90 ± 151.09 439.95 ± 148.16 0.319
1st LSM value 17.57 ± 13.68 11.97 ± 5.94 0.012
2nd LSM value 9.95 ± 6.90 15.12 ± 7.44 0.005
1st Albumin (g/dL) 4.23 ± 0.55 4.39 ± 0.25 0.083
2nd Albumin (g/dL) 4.55 ± 0.33 4.42 ± 0.28 0.140
1st T. bilirubin (mg/dL) 1.48 ± 1.74 0.99 ± 0.26 0.035
2nd T. bilirubin (mg/dL) 1.021 ± 0.38 0.929 ± 0.38 0.340
1st AST (IU/L) 93.95 ± 212.68 44.57 ± 32.86 0.294
2nd AST (IU/L) 27.29 ± 8.61 34.19 ± 15.17 0.059
1st ALT (IU/L) 113.87 ± 305.50 62.76 ± 79.06 0.452
2nd ALT (IU/L) 26.03 ± 11.86 36.24 ± 18.26 0.024
1st Platelet (103/µL) 157.80 ± 62.90 162.55 ± 37.73 0.687
2nd Platelet (103/µL) 172.12 ± 65.09 172.60 ± 40.93 0.969
1st HBeAg positivity (%) 64.2 52.6 0.377
2nd HBeAg positivity (%) 56.0 47.4 0.521
1st HBV DNA (IU/mL)* 3,994  
(0-110,000,000)
5,150  
(0-110,000,000)
0.743
2nd HBV DNA (IU/mL)* 12 (0-7,990) 12 (0-306,000) 0.727
*Median. AST, aspartate aminotransferase; ALT, alanine aminotransferase; LSM, liver 
stiffness measurement; HBeAg, hepatitis B envelop antigen; HBV, hepatitis B virus.
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with improved fibrosis stage were female predominant, and had 
lower initial LSM value and higher initial albumin level. 
Comparison of groups according to ALT levels at 1st LSM 
during antiviral therapy
It has been reported that ALT level may affect the LSM value. So 
we compared two groups accoding to ALT levels at 1st LSM time 
point (Table 5). AST, ALT, and HBV DNA levels were significant­
ly higher in the high ALT ( > upper limit of normal [ULN] × 2) 
group. However, there was no difference in sex, age, LSM mea­
surement intervals, baseline albumin, total bilirubin, and HBeAg 
positivity between two groups. The second LSM significantly 
decreased in both high ALT (> ULN × 2) and low ALT (≤ ULN 
× 2) group compared to 1st LSM (P < 0.001; P = 0.001, respec­
tively). 
DISCUSSION
Chronic HBV infection is one the most common etiologies of 
chronic liver disease in Korea (15). There are several clinical 
features of HBV­related chronic liver diseases in Korean popu­
lation (16). HBV genotype C is more than 95%, and precore and 
core promoter mutant HBV are common. Lamivudine resis­
tance is not uncommon among CHB patients who are candi­
dates for the treatment with oral nucleos(t)ide analogues in Ko­
rea. The aim of treating patients with chronic HBV infection is 
to prevent disease progression to liver cirrhosis and hepatocel­
lular carcinoma (17). Oral antiviral agents are widely used to 
suppress viral replication and to prevent disease progression. 
However, long­term antiviral therapy is usually required be­
cause of the nature of oral nucleos(t)ide analogues. After intro­
duction of potent antiviral agents such as entecavir or tenofovir, 
it becomes possible to maintain HBV viral load very low or even 
undectable during long­term antiviral therapy. Moreover, the 
reversal of hepatic fibrosis/cirrhosis was observed in patients 
Fig. 2. Changes of the proportion of the patients grouped by the fibrosis stage be-
tween two liver stiffness measurements during oral antiviral therapy. The patients’ 
initial fibrosis stages were 16 (19.3%) in F0-1, 15 (18.1%) in F2, 22 (26.5%) in F3 
and 30 (36.1%) in F4, respectively. After antiviral therapy, the patients’ fibrosis stages 
were 42 (50.6%) in F0-1, 6 (7.2%) in F2, 12 (14.5%) in F3 and 23 (27.7%) in F4, 
respectively.
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Table 4. Comparison of groups by fibrosis stage improvement during antiviral therapy 
Parameters
Fibrosis stage  
improved (n = 37)
Fibrosis stage not 
improved (n = 46)
P value
Male gender (%) 59.5 84.8 0.013
Age (yr) 51.16 ± 8.92 51.78 ± 9.36 0.760
Measurement intervals (day) 419.92 ± 164.31 404.78 ± 139.67 0.651
1st LSM value 12.47 ± 3.23 19.11 ± 15.88 0.008
2nd LSM value 7.14 ± 2.41* 14.57 ± 8.30† < 0.001
1st Albumin (g/dL) 4.41 ± 0.31 4.16 ± 0.59 0.018
2nd Albumin (g/dL) 4.60 ± 0.27 4.45 ± 0.36 0.030
1st T. bilirubin (mg/dL) 1.23 ± 1.64 1.45 ± 1.44 0.513
2nd T. bilirubin (mg/dL) 0.951 ± 0.31 1.035 ± 0.43 0.307
1st AST (IU/L) 90.95 ± 255.10 73.83 ± 102.25 0.679
2nd AST (IU/L) 25.92 ± 8.67 31.54 ± 12.05 0.019
1st ALT (IU/L) 129.76 ± 384.47 77.76 ± 103.54 0.382
2nd ALT (IU/L) 25.32 ± 12.00 31.26 ± 15.63 0.061
1st Platelet (103/µL) 172.33 ± 58.86 148.07 ± 54.56 0.060
2nd Platelet (103/µL) 182.22 ± 58.06 164.07 ± 60.50 0.178
1st HBeAg positivity (%) 59.4 62.5 0.812
2nd HBeAg positivity (%) 53.3 53.8 1.000
1st HBV DNA (IU/mL)‡ 4,682 
(0-110,000,000)
3,140 
(0-110,000,000)
0.540
2nd HBV DNA (IU/mL)‡ 12 (0-6,580) 12 (0-306,000) 0.398
*P < 0.001; †0.011 compared to 1st LSM values; ‡Median. AST, aspartate amino-
transferase; ALT, alanine aminotransferase; LSM, liver stiffness measurement; HBeAg, 
hepatitis B envelop antigen; HBV, hepatitis B virus.
Table 5. Comparison of groups by ALT levels at 1st LSM during antiviral therapy 
Parameters
Low ALT group 
(1st ALT ≤ ULN × 2, 
n = 62)
High ALT group  
(1st ALT > ULN × 2, 
n = 21)
P value
Male gender (%) 75.8 66.7 0.412
Age (yr) 51.97 ± 9.29 50.14 ± 8.65 0.431
Measurement intervals (day) 407.42 ± 138.08 423.67 ± 185.35 0.671
1st LSM value 15.52 ± 11.69 18.00 ± 14.47 0.432
2nd LSM value 11.67 ± 7.65* 10.04 ± 6.42† 0.383
1st Albumin (g/dL) 4.33 ± 0.44 4.09 ± 0.61 0.060
2nd Albumin (g/dL) 4.50 ± 0.34 4.56 ± 0.28 0.507
1st T. bilirubin (mg/dL) 1.16 ± 0.72 1.92 ± 2.74 0.224
2nd T. bilirubin (mg/dL) 1.04 ± 0.39 0.88 ± 0.31 0.105
1st AST (IU/L) 39.18 ± 39.51 206.29 ± 338.07 0.035
2nd AST (IU/L) 29.77 ± 11.26 26.86 ± 10.02 0.295
1st ALT (IU/L) 33.69 ± 16.75 299.48 ± 486.52 0.021
2nd ALT (IU/L) 29.48 ± 15.09 26.05 ± 11.84 0.346
1st Platelet (103/µL) 158.00 ± 55.08 161.76 ± 65.06 0.799
2nd Platelet (103/µL) 171.37 ± 60.16 174.67 ± 59.90 0.830
1st HBeAg positivity (%) 55.8 75.0 0.180
2nd HBeAg positivity (%) 50.0 63.2 0.328
1st HBV DNA (IU/mL)‡ 304  
(0-110,000,000)
3,200,000  
(12-110,000,000)
< 0.001
2nd HBV DNA (IU/mL)‡ 12 (0-306,000) 12 (0-7,990) 0.551
*P < 0.001; †0.001 compared to 1st LSM values; ‡Median. AST, aspartate aminotrans-
ferase; ALT, alanine aminotransferase; LSM, liver stiffness measurement; HBeAg, hep-
atitis B envelop antigen; HBV, hepatitis B virus.
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with long­term oral antiviral therapy (6). 
 Liver fibrosis results from wound healing response for chron­
ic inflammation in the liver. The stage of liver fibrosis has a good 
correlation with liver­related clinical outcome such as decom­
pensated liver cirrhosis or even development of HCC (18, 19). 
The accurate information about the extent of liver fibrosis in 
patients with CHB is clinically very important for the evaluation 
of severity of the disease, for making treatment decisions and 
for evaluating efficacy of antiviral treatment. Liver biopsy has 
long been a gold standard to assess the degree of liver fibrosis 
(11). However, because of invasive nature and risk of bleeding 
complication it is difficult to perform liver biopsy, particularly 
when it needs to be repeated in real clinical practice. Moreover, 
liver biopsy has limitations such as extremely small sampling 
size representing only 1/50,000 liver volume, intra­ or inter­ob­
server variation for the accurate assessment of liver fibrosis (20). 
 Recently noninvasive methods such as transient elastograpy, 
acoustic radiation force impulse (ARFI), Fibro­CT, MRI have 
been explored for the assessment of hepatic fibrosis (12). Liver 
stiffness measurement by fibroscan is the most widely used non­
invasive method for assessing the extent of liver fibrosis. It was 
reported that LSM discriminates significant liver fibrosis or liver 
cirrhosis (F4) with high accuracy in patients with chronic viral 
hepatitis (21, 22). Our study showed that mean LSM was de­
creased from 16.15 ± 12.41 kPa to 11.26 ± 7.36 kPa during anti­
viral therapy for an average 411 days, suggesting the regression 
of hepatic fibrosis during oral antiviral therapy. The average of 
degree of regression of liver stiffness during antiviral therapy 
was ­2.03 ± 0.36% per month. There was no statistical difference 
of degree of regression by the type of antiviral agents or presence 
of lamivudine resistance. These results might be caused by the 
small number of patients in each oral antiviral agents group, and 
should be studied further in a larger study. 
 The heterogeneous timing of LSM from the retrospective study 
design is a limitation. The 1st LSM was measured as a baseline 
before starting antiviral therapy in 33 patients (39.8%). Median 
duration of antiviral treatment to 1st and 2nd LSM time point 
was 5.3 and 17.3 months, respectively. There was no difference 
of the degree of regression of liver stiffness between the groups 
in whom initial LSM was obtained before starting antiviral ther­
apy (n = 33) and the patients in whom initial LSM was obtained 
during antiviral therapy (n = 50) (­2.54 ± 3.13 vs ­1.69 ± 3.35% 
per month, P = 0.251). Therefore it is less likely that the improve­
ment of LSM mainly resulted from lead time bias by previous 
long­term antiviral therapy.
 In our study, we adopted LSM cut­offs for fibrosis staging 
from a previous report in which Korean patients with genotype 
C HBV infection were studied. Of the 30 (36.1%) patients with 
LSM ≥ 14.1 kPa (F4) at 1st LSM, 12 (40%) proved to have im­
proved fibrosis (LSM less than 14.1 kPa) at 2nd LSM. According 
to recent meta­analysis, weighted mean LSM values were 7.9, 
8.8, and 11.7 for F ≥ 2, F ≥ 3, and F = 4 (23). When we apply cut­
offs 7.9, 8.8, and 11.7 kPa for F ≥ 2, F ≥ 3, and F = 4 from the 
meta­analysis, LSM improvement was also observed in a very 
similar manner during antiviral therapy compared with our 
current data. The fibrosis stage was improved in 39 (47.0%) be­
tween two LSMs. Thirty six (43.4%) patients showed no change 
of fibrosis stage, only 8 (9.6%) showed the aggravation of fibro­
sis stage. Of the 39 (47.0%) patients with LSM ≥ 11.7 kPa (cir­
rhosis) at 1st LSM, 17 (43.6%) proved to no longer have cirrhosis 
(≥ 1 decrease in fibrosis stage) at 2nd LSM. Taken together, these 
data indicate that oral antiviral therapy attenuates the extent of 
liver fibrosis in patients with B­viral liver cirrhosis. 
 For the assessment of hepatic fibrosis by LSM using Fibroscan, 
the following important limitation should be considered. The 
degree of hepatic necroinflammation may affect the LSM value, 
i.e., the presence of significant necroinflammation can exagger­
ate the LSM value (24­26). When we analysed the change of LSM 
during antiviral therapy with respect to baseline ALT level, the 
LSM value significantly decreased in high ALT (> ULN × 2) group 
as well as in low ALT ( ≤ ULN × 2) group, indicating that oral 
antiviral therapy decrease liver stiffness regardless of ALT ab­
normality in patients with CHB. These results suggest that the 
decrease in LSM value during oral antiviral therapy is not caused 
by purely reducing hepatic necroinflammation but at least par­
tially by decreasing hepatic fibrosis. Macronodular cirrhotic ar­
chitecture or the absence of significant histologic grade may re­
sults in false negative LSM (LSM below cutoff level of cirrhosis) 
for the accurate diagnosis of histologic cirrhosis. The absence 
or mild histologic grade during oral antiviral therapy in our study 
might cause lower 2nd LSM value resulting in the underestima­
tion of liver cirrhosis.
 Because of retrospective study design, pathologic changes 
were not verified to confirm the change of LSM in our study. In 
spite of this limitation, the demonstration of the LSM change in 
CHB patients on antiviral therapy through repeated measure­
ment of liver stiffness in real life setting provides important clin­
ical implication supporting the usefulness of LSM using Fibro­
scan for the assessment of fibrosis regression during antiviral 
treatment. Recently, Marcellin et al. demonstrated that oral an­
tiviral treatment with tenofovir regressed liver cirrhosis in chron­
ic hepatitis B patients (27). Our study provides similar results 
using repeated LSM measurement instead of repeated liver bi­
opsies in real­life practice setting. Our study result warrants fur­
ther prospective study to confirm the correlation of LSM and 
pathologic changes during oral antiviral therapy in CHB patients. 
 In conclusion, long­term oral antiviral therapy resulted in the 
improvement of liver stiffness in a substantial portion of patients 
with CHB. Liver stiffness measurement using transient elastog­
raphy may be used as a useful clinical tool to evaluate disease 
progression in CHB patients. 
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